Therapy Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Fedratinib	Inrebic	SAR302503\|TG101348	FLT3 Inhibitor 69 JAK2 Inhibitor - ATP competitive 15 RET Inhibitor 53	Inrebic (fedratinib) binds and inhibits JAK2, FLT3, and RET kinases, which may inhibit cell proliferation and tumor growth (PMID: 17541402). Inrebic (fedratinib) is FDA approved for use in patients with myelofibrosis (FDA.gov).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 27 of 27 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
JAK2 rearrange	myeloid neoplasm	sensitive	Fedratinib	Guideline	Actionable	Inrebic (fendratinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a JAK2 rearrangement (NCCN.org).	detail...
JAK3 V718L	esophagus adenocarcinoma	sensitive	Fedratinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited viability of cells derived from the brain metastases of a patient with esophagus adenocarcinoma harboring JAK3 V718L in culture (PMID: 38985431).	38985431
JAK2 R683G JAK2 L884P	Advanced Solid Tumor	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited viability of a cell line expressing JAK2 R683G and L884P in culture (PMID: 37290440).	37290440
JAK2 R867Q	hematologic cancer	decreased response	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Inrebic (fedratinib) in culture (PMID: 24398328).	24398328
JAK2 V617F	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 E1028K	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and E1028K in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 E985K	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 G935R	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 L902Q	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line expressing JAK2 V617F and L902Q was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 L902Q JAK2 E1028K	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and E1028K was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 L902Q JAK2 R938E	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R938E was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 L902Q JAK2 R947Q	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R947Q was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 L983F	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 M929I	hematologic cancer	predicted - sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 M929I double mutation were sensitive to treatment with Inrebic (fedratinib) in culture, demonstrating growth inhibition (PMID: 21926964).	21926964
JAK2 V617F JAK2 Q959H	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and Q959H in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 Q959H JAK2 L983F	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 R938E	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and R938E in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 R947Q	hematologic cancer	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 Y931C	Advanced Solid Tumor	sensitive	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) treatment inhibited colony formation and proliferation of transformed cells expressing JAK2 V617F and Y931C in culture (PMID: 26419724).	26419724
JAK2 V617F JAK2 Y931C	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2 V617F JAK2 Y931C	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and Y931C in culture (PMID: 39091915).	39091915
JAK2 V617F JAK2 Y931C JAK2 F1061W	Advanced Solid Tumor	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and F1061W demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).	26419724
JAK2 V617F JAK2 Y931C JAK2 S1025C	Advanced Solid Tumor	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and S1025C demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).	26419724
JAK2 V617F JAK2 Y931C JAK2 V1075F	Advanced Solid Tumor	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and V1075F demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).	26419724
JAK2 V617F JAK2 Y931C JAK2 Y1045W	Advanced Solid Tumor	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and Y1045W demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).	26419724

Showing 1 to 27 of 27 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 4 of 4 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03952039	Phase III	Fedratinib	An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)	Active, not recruiting	POL \| NLD \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| BEL \| AUT \| AUS	3
NCT05177211	Phase II	Fedratinib	Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)	Active, not recruiting	USA	0
NCT03755518	Phase III	Fedratinib	An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)	Terminated	USA \| CAN	0
NCT05127174	Phase Ib/II	Fedratinib	Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms	Terminated	USA	0

Showing 1 to 4 of 4 entries

Filter rows:

Therapy Detail

Contact

Filtering

Sorting

Filtering

Sorting

Filtering

Sorting

Additional content available in CKB BOOST